Table 2 Univariate and Multivariate Analysis of Factors Affecting Disease-Free Survival (DFS) and Overall Survival (OS)

Factors

Unitivariate analysis of DFS

Multivariate analysis of DFS

HR

95%CI

p-value

HR

95%CI

p-value

Surgery (TM vs. NSM/SSM)

1.635

0.962–2.780

0.069

Axillary procedure (SLNB vs. ALND)

3.302

0.654–2.120

0.011

2.179

0.826–5.751

0.116

Age (< 35 vs. ≥ 35)

1.177

0.654–2.120

0.586

Size (< 2 vs. ≥ 2)

1.552

0.858–2.806

0.146

Quadrant (central zone vs. upper inner)

0.779

0.235- 4.710

0.585

Quadrant (central zone vs. lower inner)

1.523

0.317- 1.911

0.431

Quadrant (central zone vs. upper outer)

0.968

0.535- 4.338

0.93

Quadrant (central zone vs. lower outer)

1.47

0.472- 1.989

0.361

Distance from nipple (< 2 vs. ≥ 2)

1.73

0.917–3.264

0.091

pT (1 vs.2–3)

1.558

1.336–4.226

0.014

1.256

0.628–2.511

0.520

Node status (positive vs. negative)

1.48

0.863–2.538

0.154

Stage (1 vs. 2–3)

3,873

1.660–9.035

0.002

2.701

1.092–6.68

0.031

Neoadjuvant chemotherapy

1.037

0.470–2.285

0.929

Radiotherapy

2.949

1.742–4.992

 < 0.001

1.978

1.123–3.484

0.018

Post mastectomy chemotherapy

1.019

0.141- 7.378

0.985

Endocrine therapy

0.899

0.492- 1.642

0.729

Targeted therapy

5.892

3.509–9.893

 < 0.001

5.584

3.323–9.382

 < 0.001

ER

0.846

0.470–1.523

0.577

PR

0.617

0.363–1.049

0.074

Ki67

1.385

0.818–2.346

1.385

HER2

0.756

0.435–1.313

0.32

Nodules on ultrasound (1 vs. ≥ 2)

0.901

0.477–1.703

0.748

Multifocal cancer

1.893

0.460–7.781

0.377

Calcify

1.295

0.742–2.260

0.363

Factors

Unitivariate analysis of OS

Multivariate analysis of OS

HR

95%CI

p-value

HR

95%CI

p-value

Surgery (TM vs. NSM/SSM)

1.369

0.606–3.09

0.45

Axillary procedure (SLNB vs. ALND)

7.029

0.944–52.317

0.057

Age (< 35 vs. ≥ 35)

0.781

0.328–1.86

0.577

Size (< 2 vs. ≥ 2)

1.904

0.76–4.774

0.17

Quadrant (central zone vs. upper inner)

1.086

0.13–9.067

0.94

Quadrant (central zone vs. lower inner)

0.758

0.085–6.782

0.804

Quadrant (central zone vs. upper outer)

0.949

0.121–7.417

0.96

Quadrant (central zone vs. lower outer)

1.26

0.14710.789

0.833

Distance from nipple (< 2 vs. ≥ 2)

1.355

0.533–3.444

0.523

pT (1 vs.2–3)

2.953

1.186–7.355

0.02

0.578

0.461–4.001

0.493

Node status (positive vs. negative)

1.651

0.732–3.727

0.227

Stage (1 vs. 2–3)

10.32

1.393–76.435

0.022

8.309

0.927–74.458

0.021

Neoadjuvant chemotherapy

0.327

0.044–2.419

0.273

Radiotherapy

0.528

0.245–1.140

0.055

Post mastectomy chemotherapy

20.654

0.000–23911

0.669

Endocrine therapy

0.45

0.197–1.028

0.058

Targeted therapy

2.084

0.873–4.978

0.098

ER

0.49

0.214–1.119

0.091

PR

0.357

0.16–0.794

0.012

0.350

0.155–0.768

0.010

Ki67

1.473

0.727–2.988

0.283

HER2

0.634

0.262–1.527

0.314

Nodules on ultrasound (1 vs. ≥ 2)

0.689

0.235–2.016

0.496

Multifocal cancer

0.048

0.000–12897.0

0.634

Calcify

1.425

0.609–3.336

0.414